(Q33383423)

26 July 2017

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study (English)

1 reference

26 July 2017

1 reference

T André

1

0 references

author name string

J M Reyes-Vidal

2

1 reference

26 July 2017

L Fartoux

3

1 reference

26 July 2017

P Ross

4

1 reference

26 July 2017

M Leslie

5

1 reference

26 July 2017

O Rosmorduc

6

1 reference

26 July 2017

M R Clemens

7

1 reference

26 July 2017

C Louvet

8

1 reference

26 July 2017

N Perez

9

1 reference

26 July 2017

F Mehmud

10

1 reference

26 July 2017

W Scheithauer

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

British Journal of Cancer

26 July 2017

1 reference

26 July 2017

99

1 reference

26 July 2017

862-867

1 reference

26 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604628

26 July 2017

0 references

cites work

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Review of gemcitabine in biliary tract carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Worldwide trends in mortality from biliary tract malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Epidemiology and molecular pathology of gallbladder cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

21 June 2018

Biliary tract cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538748

Gallbladder cancer, a different disease that needs individual trials

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604628

Second-line treatment of ovarian cancer with single-agent gemcitabine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604628

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604628

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study

21 January 2018

1 reference

12 December 2020

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

1 reference

12 December 2020

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604628

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference